BET protein inhibition shows efficacy against JAK2V617F driven neoplasms by Wyspiańska, BS et al.
BET protein inhibition shows efficacy 
against JAK2V617F driven neoplasms 
 
 
 
 
 
Beata Wyspianska1*, Andrew J. Bannister1*, Isaia Barbieri1*, Jyoti 
Nangalia2,3, Anna Godfrey2,3, Fernando J. Calero-Nieto2, Samuel 
Robson1, Inmaculada Rioja4, Juan Li2,3, Meike Wiese1,2, Ester 
Cannizzaro1,2, Mark A. Dawson1,2,3, Brian Huntly2, Rab K. Prinjha4, 
Anthony R. Green2,3, Berthold Gottgens2, Tony Kouzarides1♯  
 
 
 
 
 
 
1Gurdon Institute and Department of Pathology, University of Cambridge, Tennis Court Road, 
Cambridge, CB2 1QN, UK 
 
2Department of Haematology, Cambridge Institute for Medical Research and The Wellcome 
Trust and MRC Stem Cell Institute, University of Cambridge, Cambridge, CB2 0XY, UK 
 
3Addenbrooke’s Hospital, University of Cambridge, Cambridge, CB2 0XY, UK 
 
4Epinova DPU, Immuno-Inflammation Centre of Excellence for Drug Discovery, 
GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, 
UK. 
 
 
 
 
Condensed title: BET inhibition in JAK2V617F driven neoplasms. 
 
 
Keywords: JAK2V617F, BET proteins, LMO2, Myeloproliferative Neoplasms 
 
 
 
 
 
* These authors contributed equally to this work. 
 
♯ Corresponding author 
Gurdon Institute and Department of Pathology 
University of Cambridge 
Tennis Court Road 
Cambridge, CB2 1QN, UK 
Telephone: +44 1223334112 
Fax: +44 1223334089 
Email: t.kouzarides@gurdon.cam.ac.uk 
 
Abstract 
 
Small molecule inhibition of the BET family of proteins, which bind acetylated 
lysines within histones, has been shown to have a marked therapeutic benefit 
in pre-clinical models of MLL-fusion protein driven leukemias. Here, we report 
that I-BET151, a highly specific BET family bromodomain inhibitor, leads to 
growth inhibition in a human erythroleukemic (HEL) cell line as well as in 
erythroid precursors isolated from polycythemia vera patients.  One of the 
genes most highly down regulated by I-BET151 was LMO2, an important 
oncogenic regulator of hematopoietic stem cell development and 
erythropoiesis. We previously reported that LMO2 transcription is dependent 
upon JAK2 kinase activity in HEL cells. Here, we show that the transcriptional 
changes induced by a JAK2 inhibitor (TG101209) and I-BET151 in HEL cells 
are significantly over-lapping, suggesting a common pathway of action. We 
generated JAK2 inhibitor resistant HEL cells and showed that these retain 
sensitivity to I-BET151. These data highlight I-BET151 as a potential 
alternative treatment against myeloproliferative neoplasms driven by 
constitutively active JAK2 kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Introduction 
 
Myeloproliferative neoplasms (MPNs) include a group of diverse and 
heterogeneous clonal stem cell disorders characterized by overproduction of 
one or more blood cell types (1-3). They include polycythemia vera (PV), 
essential thrombocythemia (ET), and primary myelofibrosis (PMF). At the 
molecular level these pathologies are very often associated with the presence 
of a gain of function point mutation in the Janus kinase JAK2, JAK2V617F (4-
7). Indeed, the importance of JAK2 mutation in myeloproliferation has been 
demonstrated both in vitro and in vivo using a variety of techniques (5, 6, 8, 9, 
10). Furthermore, recent evidence also indicates that the activity of JAK2 can 
directly control the expression of leukemic transcription factors such as LMO2. 
It has been shown that JAK2V617F can translocate to the nucleus and 
phosphorylate tyrosine 41 of histone H3 to prevent binding of HP1α to the 
promoter of LMO2 (ref. 11).  
 
Current treatment of MPNs commonly involves phlebotomy and the use of 
antiproliferative agents such as hydroxycarbamide. Although hydroxy-
carbamide is safe and effective, resistance or intolerance in patients is not 
uncommon.  In addition, antiproliferative agents do not alter the natural history 
of the MPN, particularly the risk of transformation to myelofibrosis or acute 
myeloid leukemia (12). Therefore, there is a need to develop agents with 
better clinical efficacy for the treatment of MPNs. 
 
The importance of JAK2 in the development of overactive myeloproliferation 
promoted efforts to develop small molecule inhibitors of JAK2 activity in vivo. 
Very recently these efforts have seen the approval of a JAK2 inhibitor, 
Ruxolitinib, for the treatment of myelofibrosis (13, 14). However, it is important 
to stress that JAK2 also plays a crucial role in normal hematopoiesis, as well 
as a host of other physiological processes, and so the levels of JAK inhibitors 
used in clinical settings are limited by potential widespread toxicity. Indeed, 
consistent with this perception, treatment of myelofibrosis patients with the 
licensed dose of Ruxolitinib is associated with only a modest decrease in 
JAK2V617F allele burden (15). Furthermore, chronic exposure to JAK 
inhibitor therapy induces ‘persistence’ in in vitro cultured MPN cells, as well as 
in Ruxolitinib treated samples isolated from MPN primary patients (16). There 
is a clear need therefore to develop further drugs in order to achieve 
molecular remission in MPN patients, to be used either as sole agents or in 
combination therapy.  
 
Recently, the BET proteins have emerged as a very exciting group of 
transcriptional co-regulators. They are chromatin readers recognising 
acetylated lysines in histones (17), and comprise 4 proteins, BRD2, BRD3, 
BRD4 and BRDT. Each protein possesses two highly conserved 
bromodomains. Their main function is to recruit members of the pTEF-b 
complex to promoters to support transcriptional elongation, and their 
functional importance is underscored by their links to cancer when they 
become dysregulated (18, 19).  
 
We, and others, have recently established the therapeutic efficacy of a novel 
class of epigenetic compounds that selectively target the BET proteins. The 
BET inhibitors selectively bind to the bromodomains of the BET proteins and 
inhibit their ability to bind acetylated lysine residue on histones. The 
therapeutic benefit of BET inhibitors has been demonstrated in pre-clinical 
models of MLL-FP leukemia (19, 20), in AML cell lines lacking MLL 
rearrangements as well as in multiple myeloma and in Burkitt’s lymphoma (21, 
22). 
 
In this manuscript we have investigated the efficacy of a potent BET inhibitor 
(GSK151A - hereafter referred to as I-BET151) in JAK2 driven neoplastic 
cells, employing human erythroleukemic (HEL) cells as an in vitro model 
system, as well as primary patient samples. We found that I-BET151 
efficiently prevented HEL cell proliferation, and induced apoptosis, at least in 
part, via down-regulation of the LMO2 gene. LMO2 is also down-regulated by 
JAK2 inhibitors and we found that I-BET151 and a JAK2 inhibitor (TG101209 - 
hereafter referred to as JAK2i) cooperate to down-regulate expression of 
LMO2 and inhibit HEL cell proliferation. We then investigated whether I-
BET151 shows efficacy against a JAK2V617F-driven human MPN, namely 
PV. We report that I-BET151 efficiently inhibits erythroid colony formation 
from JAK2 mutant but not wild type JAK2 containing erythroid colonies 
cultured from PV patients. Our results highlight the potential for the use of I-
BET151 against JAK2-driven neoplasms, especially PV, with the added 
possibility that this new treatment may reduce disease burden. Furthermore, 
we provide evidence that the use of I-BET151 in conjunction with JAK2i, may 
overcome acquired resistance to JAK2 inhibitors.   
 
 
Materials and methods 
 
Cell Culture  
Human erythroleukemia (HEL) and human myelogenous leukemia (K562) 
cells were maintained in RPMI 1640 medium, 10% FBS, 1% 
penicillin/streptomycin/glutamine (GIBCO, Invitrogen), incubated at 37°C in 
5% CO2 and passaged 1:6 every 2-3 days. 
 
Compounds  
TG101209 JAK2 inhibitor was from TargeGen Inc. and GSK1210151A (I-
BET151) was provided by GlaxoSmithKline.  
 
Immunoblotting 
Whole cell lysates, prepared in 2X Laemmli sample buffer, were separated by 
SDS-PAGE and transferred to nitrocellulose (Millipore). Signal was detected 
using ECL® (GE Healthcare) and developed on X-ray film (Fuji). A list of 
antibodies is in the Supplementary information. 
 
Cell Growth Inhibition (GI50) Assay 
HEL and K562 cells (1 x 105 cells/ml) were seeded at 200µl/well. TG101209 
and I-BET151 (in DMSO) were serially diluted. Cell growth inhibition was 
assessed via CellTiter-Glo® luminescent viability assay (Promega), following 
the manufacturer’s instructions.  
 
Proliferation assays 
1x105 HEL and K562 cells were plated in complete medium containing 
TG101209, I-BET151 or DMSO. Viable cells were counted twice at each time 
point using a Countess counter (Invitrogen).  
 
Clonogenic Assays in Methylcellulose  
Clonogenic potential of HEL and K562 cells was assessed via colony growth 
in the presence of DMSO or 1µM I-BET151. Cells were plated in 
methylcellulose supplemented with human cytokines (Methocult H4435, 
Stemcell Technologies) in duplicate at 1x102 and 1x103 per plate. Colonies 
were analysed 7-10 days after seeding. 
 
Human samples and assays 
All patients gave written informed consent; the study was approved by the 
Cambridge and Eastern Region Ethics Committee, and research was carried 
out in accordance with the Declaration of Helsinki. The selection of patients 
and colonies analysis were performed as previously described (23). Following 
isolation of PMNCs from PV5, lineage negative cells enriched for 
hematopoietic progenitors were obtained by magnetic separation as per 
manufacturer's instructions (Human Progenitor Enrichment Kit, Easysep, 
Stem cell Technologies). Cells were incubated in DMEM, 15% FBS, 1Uml 
EPO and either DMSO, 200nM or 1uM I-BET151. Cells were lysed in Trizol 
and RNA extraction was performed using phenol/chloroform.  
 
Flow Cytometry   
Apoptosis was assessed using Annexin V-FITC kit (Miltenyi Biotec Ltd.) 
supplemented with 7-AAD (BD bioscience), according to the manufacturer’s 
instructions. Flow cytometry experiments were performed on a CyAn ADP 
flow cytometer (Dako), and data were analysed with FlowJo software (Tree 
Star, Inc.).  
 
Chromatin Immunoprecipitation (ChIP) Assay 
HEL cells were treated with 1µM I-BET151 or DMSO for 4 hours. ChIP was 
carried out as previously described (11).  
 
Quantitative Real-Time RT-PCR 
Cells were treated for 4 hours with TG101209, I-BET151 or DMSO. mRNA 
was extracted from equal numbers of cells using the RNAeasy kit, Qiagen, 
following the manufacturer's protocol. First-strand cDNA was synthesized 
using the SuperScript™ III Reverse Transcriptase kit (Invitrogen).  Analysis of 
ChIP and cDNA samples was carried out on an ABI 7900 real-time PCR 
machine, using fast SYBR®green PCR Master Mix (ABI) according to the 
manufacturer's instructions. Primers used in this study are listed in the 
Supplementary Information. 
 
 
 
Lentiviral Production and Transduction 
shRNA against LMO2 (in pLL3.7 vector) was kindly provided by Dr. Jiro 
Kikuchi (Jichi Medical University, Japan (24)). Lentivirus production was 
carried out as previously described (25) 
 
Flow cytometry and Competitive proliferation assay 
GFP fluorescence analysis was performed using a Cyan ADP analyser 
(Beckman Coulter, High Wycombe, UK). Competitive proliferation assays in 
liquid culture were performed by monitoring the GFP-positive cell-fraction over 
a 13-day time-course. 
 
Gene Expression and Bioinformatic Analysis 
HEL cell RNA (treated with 1µM I-BET151 or TG101209) was extracted after 
4 hours and processed as described before after hybridisation to Illumina 
Human HT12 v4 BeadChips. Gene expression data were analysed as 
previously described (19). 
 
 
Results 
 
Using an end-point viability assay, we have recently shown that HEL cells are 
sensitive to I-BET151 treatment with an IC50 of approximately 1µM (19). To 
further investigate the effect of I-BET151 on HEL cells we performed a cell 
proliferation assay over a range of I-BET151 concentrations (Figure 1A). 
These data clearly show that HEL cells are acutely sensitive to I-BET151 
exposure, exhibiting an IC50 of 300nM in this assay. In contrast, K562 cells 
were less effected by I-BET, exhibiting an IC50 of 6µM; 20-fold greater than 
the IC50 in HEL cells (Figure 1A). Consistent with the strong effects in liquid 
culture, the colony-forming potential of HEL cells was significantly reduced by 
I-BET151, whereas K562 cells were unaffected (Figure 1B). 
We next asked whether I-BET151 treatment induces apoptosis in HEL cells, 
as it does in MLL-fusion driven cell lines. Figure 1C shows that two markers of 
apoptotic cells, cleaved PARP and active CASPASE 3, are both detectable 
after 24 hours exposure to I-BET151 and expression of both is significantly 
up-regulated after 48 hours exposure. A high level of I-BET151 induced 
apoptosis was also detected via FACS analysis, where 30% of cells were 
positive for ANNEXIN V staining after a 48h treatment with 1µM I-BET151 
(Figure 1D) compared to just 3% positive cells in DMSO treated cells. These 
data suggest that I-BET151 alters transcriptional programmes in HEL cells 
that ultimately regulate apoptosis.  
To identify the precise transcriptional pathways controlled by I-BET151, global 
gene-expression analyses were performed in HEL cells after treatment with 
1µM I-BET151 or DMSO for 4 hours. This strategy allowed us to identify early, 
and most likely directly regulated, I-BET151-responsive genes. As 
demonstrated previously in MLL-driven cells, we observed in HEL cells 
differential expression of only a selective subset of genes rather than global 
transcriptional dysregulation; using a cut-off threshold of 2-fold, 125 genes 
were down-regulated, and 154 genes up-regulated by I-BET151 treatment 
(Figure 2A and Supplementary Figure 1) Strikingly, the third most down-
regulated gene (from over 19,000 probes on the array) was LMO2 (Figure 
2B), an important regulator of hematopoietic stem cell development and 
erythropoiesis. I-BET151 induced changes in LMO2 mRNA levels were 
confirmed by RT-PCR, and changes in LMO2 protein levels were detected by 
Western blotting (Figure 2C and D). Furthermore, changes in expression of 
three of the most down-regulated genes (LMO2, MYB and NEK6), and a 
control gene whose expression did not change (CISH), were validated directly 
by RT-PCR in a least two separate experiments (Supplementary Figure 2). 
Given the importance of LMO2 to hematopoietic stem cell development, 
leukemogenesis and erythropoiesis we decided to focus on this gene in order 
to better understand how the BET inhibitors exerted their effects in HEL cells.  
The LMO2 gene contains 3 transcriptional start sites (26) (TSSs; sites 1, 2 
and 3 in Figure 3A).  Using chromatin immunoprecipitation (ChIP) analysis, 
we found the active gene marker H3K4me3 at the three TSSs, especially at 
the proximal (site 1) and intermediate (site 2) TSSs but not at an upstream 
region (site 4; Figure 3A). Importantly, we also found significant levels of 
BRD3 and 4 at the TSSs which were dramatically reduced after treatment with 
I-BET151. ChIP of the elongation competent form of RNA polymerase II, 
phosphorylated at serine 2 within its CTD by the BRD3/4 recruited cdk9 
kinase, indicated that the active polymerase is present primarily at the 
proximal and intermediate TSSs and that exposure to I-BET151 significantly 
reduces the amount of transcriptionally competent polymerase (Figure 3B). 
Finally, the BET proteins associate with the RNA polymerase II associated 
factor complex (PAFc) to promote transcription. ChIP with antibodies against 
LEO1, an integral PAFc member shows that LEO1 is indeed present within 
the LMO2 locus, especially at the proximal and intermediate TSSs, and that it 
is displaced by I-BET151 treatment (Figure 3B). These observations provide 
mechanistic insight into how the LMO2 gene is down-regulated upon I-
BET151 treatment. 
We next addressed whether I-BET151-mediated repression of LMO2 is 
sufficient to inhibit HEL cell proliferation.  To this end, we transduced HEL 
cells with previously validated retroviral constructs expressing shRNAs 
against LMO2 together with a GFP reporter gene (24) to allow identification of 
transduced cells. We then monitored the ability of the transduced cells to 
proliferate relative to non-transduced cells.  The results clearly indicate that 
cells transduced with shRNAs against LMO2 are rapidly out-grown by non-
transduced cells (Figure 4A).  In contrast, cells transduced with control 
shRNAs proliferate at the same rate as non-transduced cells. Importantly, 
shRNAs targeting LMO2 mRNA caused a dramatic reduction in LMO2 protein 
levels (Figure 4B). In contrast, K562 cells transduced with shRNAs against 
LMO2 did not show any growth disadvantage compared to the cells treated 
with control shRNAs (Supplementary Figure 3) Together, these data indicate 
that HEL cells require LMO2 for efficient cellular proliferation and they strongly 
implicate the LMO2 gene as a major target for the efficacy of I-BET151 in HEL 
cells. Consistent with this notion, targeted inhibition of LMO2 in HEL cells 
induced apoptosis (Figure 4C) similarly to treatment of the cells with I-BET-
151 (Figure 1C and D).  
We previously reported transcriptional regulation of the LMO2 locus by 
JAK2V617F in HEL cells. We also evaluated the global gene expression 
effect of JAK2 inhibition in HEL cells using the JAK2–specific inhibitor 
TG101209 (JAK2i; Dawson et al, 2009). LMO2 appeared within the first 
twenty most down-regulated genes after JAK2 inhibition in HEL cells. To 
better evaluate the common features of JAK2 and BET inhibition, the global 
gene expression effects of the two inhibitors were compared. The gene 
expression changes induced by the inhibitors are highly correlated showing a 
Pearson correlation coefficient of 0.683 (Figure 5A). We also identified a 
consistent overlap between the two datasets comparing the most differentially 
expressed genes. We found that 38% (48 out of 125) of I-BET151 down-
regulated genes are also down-regulated by JAK2i (Figure 5C). Similarly, 
31% (48 out of 154) of I-BET151 up-regulated genes are also up-regulated by 
JAK2i (Figure 5D).  Together, these data indicate a striking overlap between 
the genes regulated by I-BET151 and those regulated by JAK2i, suggesting 
that these compounds function in the same or very similar pathways. Indeed, 
this notion is reinforced by the observation that the two compounds have 
similar effects on HEL cells, inducing arrest of growth and apoptosis with 
comparable IC50s (Supplementary Figure 4). 
To further investigate the possibility that I-BET151 and JAK2i function in a 
common pathway we tested the two inhibitors together, in a combinatorial 
manner. To this end, we analysed a wide range of concentrations of both 
inhibitors, both separately and combined, in 72h proliferation assays. I-
BET151 and JAK2i showed an additive effect for all concentrations tested 
(Figure 5D and Supplementary Figure 5). We also tested the combined effect 
of the two inhibitors on the expression of LMO2. Once again we find that the 
two compounds act in an additive manner (Figure 5E). Furthermore, each 
inhibitor has a maximal effective dose with respect to LMO2 inhibition. Once 
this level of LMO2 inhibition has been reached the gene becomes insensitive 
to further additions of either inhibitor (Supplementary Figure 6). This strongly 
suggests that the inhibitors are functioning in a very similar manner.  As with 
the global gene expression analysis and cell proliferation analysis described 
above, these data are fully consistent with I-BET151 and JAK2i sharing key 
downstream targets.  
The LMO2 promoter is under the control of JAK2 and constitutive activation of 
the pathway, by JAK2V617F, leads to dysregulated expression of LMO2 (11). 
Furthermore, LMO2 expression is very sensitive to JAK2 inhibition (27). The 
JAK2V617F mutation is also tightly linked to multiple MPNs especially PV. 
Indeed, JAK2 inhibitors are now being used in clinical trials in the treatment of 
PV, but the mechanism(s) of their action downstream of JAK2 remain 
uncertain. Since enforced expression of LMO2 in progenitor cells increases 
erythroid differentiation enhancing transcription of erythroid genes, we 
reasoned that the dysregulated drive to produce red blood cells in PV might 
be due to constitutively active JAK2 (JAK2V617F) inducing production of 
aberrantly high levels of LMO2 protein in red blood cell progenitors. If so, I-
BET151 might provide an alternative treatment for PV patients by reducing 
LMO2 levels and consequently diminishing the drive to erythropoiesis. To 
investigate this possibility, circulating hematopoietic progenitors purified from 
a JAK2V617F positive PV patient were incubated with either DMSO vehicle or 
I-BET151 (200nM or 1µM) for 4 hours and the levels of LMO2 mRNA were 
determined via RT-PCR.  Figure 6A clearly shows that treatment of the 
progenitor cells with I-BET151 induces a dose-dependent decrease in LMO2 
mRNA levels irrespective of which housekeeping gene the data are 
normalized to (ACTIN and GAPDH, Figure 6A). 
We next asked whether exposure to I-BET151 decreases the erythroid colony 
potential of hematopoietic cells from a single PV patient in cytokine-
supplemented methylcellulose containing just DMSO vehicle or increasing 
concentrations of I-BET151 (Figure 6B). We genotyped a total of 187 BFU-E 
colonies in order to identify those that were wildtype (WT) for JAK2 and those 
that were heterozygous or homozygous for the JAK2V617F mutation (Figure 
6B). We found that I-BET151 treatment inhibits erythroid colony formation by 
cells containing mutated JAK2V617F - both heterozygous and homozygous 
cells in the case of this patient (Figure 6B). At the highest concentration of I-
BET151 (1µM) the treatment significantly reduced total colony number (only 
47 BFU-Es grew) suggesting cytotoxicity effects at this top concentration.  In 
contrast however, 200nM I-BET151 treatment reduced colonies from 
JAK2V617F containing cells, especially homozygous cells, whilst having little 
or no effect on WT JAK2 colonies. This was a striking result and it prompted 
us to investigate the effect in erythroid progenitors from additional patients.  
Consequently, we repeated the BFU-E colony-forming assay in three 
additional patients (Figure 6C). We performed these assays at 200nM I-
BET151 since this concentration showed negligible effect on total BFU-E 
colony numbers (Figure 6B). The data indicated that in all the primary cultures 
200nM I-BET151 had a significant effect on JAK2V617F-mutant colonies, 
especially those homozygous for the mutation, with no negative effect on WT 
JAK2 colonies.  To confirm this, Poisson regression analyses were performed 
for either count of total mutant colonies, or of homozygous mutant colonies, 
with total colonies as an offset, also controlling for the effect of differences 
between individuals. These analyses indicated that the proportion of total 
mutant or homozygous mutant colonies is reduced with addition of 200nM 
iBET (p=0.003 and p<0.001 respectively).  In two of the patient samples (PV2 
and PV4) there was a clear reduction in total colonies formed - however, this 
is not a drug toxicity effect because the total number of WT JAK2 colonies in 
each case were actually slightly increased by I-BET151 treatment. Thus, the 
growth inhibitory effect is limited to the progenitor cells carrying JAK2V617F. 
As discussed above, the clinical efficacy of JAK2 inhibitors is far from optimal. 
Despite a beneficial effect on the symptoms associated with myelofibrosis, 
JAK2i treatment does not lead to a significant reduction in the burden of 
JAK2V617F positive cells. Unfortunately, a significant number of patients 
develop adverse effects that lead to suspension or reduction of the drug 
dosage (15, 28). Furthermore, a recent study showed that cell lines carrying 
the JAK2V617F mutation (including HEL cells) could become reversibly 
persistent to JAK2i without new mutations appearing or clonal selection 
occurring, highlighting this as a potential problem for patients being treated 
with JAK2i. Our data suggest that the two inhibitors have similar effects on 
HEL cell transcription programmes and that they may function in the same or 
highly over-lapping pathways. Therefore, we decided to test the ability of HEL 
cells to develop resistance to I-BET151. To do this, HEL cells were treated 
constantly with the IC20 of each inhibitor (I-BET151 or JAK2i as positive 
control) or DMSO as determined in Supplementary Figure 7. Cells were 
counted and cultures split at the same rate every three days. The 
concentration of inhibitor was progressively increased according to the flow 
chart in Figure 7A. As expected, HEL cells rapidly developed resistance to 
JAK2i and they were able to grow in 500nM JAK2i after 30 days of continuous 
treatment (Figure 7B). The resistant cells were unable to persist at 
concentrations of JAK2i greater than 500nM, as previously reported (16). In 
contrast, HEL cells treated constantly with I-BET151 developed only a very 
moderate resistance and only after 30 days of treatment with no subsequent 
rise (Figure 7C). Finally, we tested the cross sensitivity of the persistent cells 
to the two inhibitors. Naïve HEL cells, DMSO chronically treated cells, JAK2i 
persistent cells and I-BET151 persistent cells were treated with 250nM JAK2i 
(Figure 7D) or 125nM I-BET151 (Figure 7E). As expected, the JAK2i 
persistent cells showed no sensitivity to JAK2i whilst the cells chronically 
treated with DMSO showed growth inhibition comparable to naive HEL cells. 
On the other hand, the I-BET151 persistent cells showed a slightly decreased 
sensitivity to 125nM I-BET151 compared to naïve HEL or cells chronically 
treated with DMSO. Importantly though, the JAK2i highly persistent cells 
remained completely sensitive, if not hypersensitive, to I-BET151. Also, the I-
BET151 persistent cells showed an unchanged sensitivity to JAK2i. Both 
JAK2i persistent and I-BET151 persistent cells maintain their sensitivity to 
high concentrations of the two inhibitors (Supplementary Figure 8). These 
results indicate that the moderate resistance achieved by JAK2V617F 
expressing HEL cells to I-BET151 occurs over a much longer time than the 
significant acquired resistance to JAK2i. Most importantly though, persistent 
cells retain sensitivity to the other inhibitor.  
Discussion 
In this paper, we have shown that a BET protein inhibitor decreases the 
proliferation and survival of human erythroleukemic cells.  We report that this 
sensitivity is due, at least in part, to I-BET151 inhibiting expression of the 
LMO2 gene. LMO2 was originally identified as a T-ALL oncogene, and has 
long been known as a positive regulator of erythroid differentiation (29). More 
recently, sustained expression of LMO2 was also shown to be required for 
growth of a subset of preB-ALL leukemias (24) even though LMO2 activation, 
in contrast to T-ALL, does not represent a recognised initiating event in this 
type of leukemia. Importantly, normal B-cell development does not require 
LMO2 as shown elegantly using conditional knock-out mice (30), thus 
establishing LMO2 as a potentially significant therapeutic target in preB-ALL 
leukemias.  Moreover, elevated LMO2 expression has also recently been 
shown to be required for proliferation of an AML cell line carrying an MLL 
translocation, as well as primary mouse bone marrow progenitors transduced 
with an MLL-ENL retrovirus (25). This study again observed exquisite 
sensitivity of the MLL-ENL transduced progenitor cells to lowering LMO2 
levels, whereas the growth of non-leukemic multipotential progenitor cells was 
unaffected.  
LMO2 is therefore rapidly emerging as a major therapeutic target for a range 
of hematopoietic malignancies, yet given its nature as a small nuclear protein, 
it has been difficult to think of efficient therapeutic strategies by which its 
inhibit its action.  By showing efficient down-regulation of the LMO2 gene in 
both cell lines and primary patient samples through the use of specific small 
molecule inhibitors, the current manuscript for the first time provides a 
strategy for LMO2 inhibition that should be readily transferable to clinical trial 
settings. Further rationale for such approaches is provided by the recurring 
theme that neoplastic cells appear to be more sensitive to LMO2 inhibition 
than their non-malignant counterparts. 
How the reduction in LMO2 levels leads to loss of cellular proliferation is not 
clear but presumably it involves reduced expression of downstream LMO2 
target genes, a number of which have been shown to promote cell 
proliferation and self renewal (31). Furthermore, specific reduction of LMO2 in 
HEL cells via shRNA targeting not only reduced cellular proliferation but it also 
induced apoptosis, indicating LMO2 regulates genes controlling cell death. 
Although our global transcriptome analysis indicates that LMO2 was the third 
most repressed gene, there were other notable significantly repressed genes 
highlighted in this analysis. For example, a number of anti-apoptotic genes, 
such as BCL2L1, were identified.  The combined action of this class of genes, 
together with the effects of LMO2 depletion, presumably explains the I-
BET151-induced apoptosis. Indeed, BET inhibition induced apoptosis, via 
inhibition of anti-apoptotic genes, seems to be a common mechanism 
operating across different cell types (19-21). 
The transcriptional effects of JAK2i and I-BET151 display a high degree of 
correlation indicating that the BET proteins and JAK2 signaling can converge 
on the same transcriptional regulatory processes. It seems likely that one role 
of JAK2V617F is to maintain a high level of transcription at the LMO2 locus. 
We believe the present study extends our understanding of the transcriptional 
control of LMO2 by placing the BET proteins in the same regulatory pathway 
as JAK2. Together, these data indicate that the BET proteins and JAK2 are 
involved in a common transcriptional regulation system controlling a specific 
subset of genes, including the sustained expression of LMO2. 
Our findings suggest that inappropriate LMO2 expression is a molecular 
feature of PV. LMO2 mRNA is expressed in progenitor cells from PV patients 
and its expression is rapidly and robustly reduced when the cells are exposed 
to I-BET151. This correlates tightly with the ability of I-BET151 to block colony 
formation from these progenitor cells.  In particular, I-BET151 is especially 
potent in preventing growth of colonies derived from homozygous JAK2V617F 
progenitor cells.  In PV, expansion of a dominant homozygous JAK2V617F 
subclone appears to be fundamental to erythrocytosis and disease 
progression in many PV patients (23).  Thus, our findings indicate that I-
BET151 treatment against PV may be highly effective as the compound 
specifically targets JAK2 mutant cells, especially homozygous JAK2V617F 
cells. This finding may have important implications for the propensity of MPN 
to progress. Using the analogy of Imatinib where BCR-ABL+ hematopoiesis is 
specifically targeted and normal hematopoiesis is restored, significant clonal 
response, as our results suggest for I-BET treatment, translates into a 
decreased progression to advanced disease. 
Continuous treatment of JAK2V617F positive cells with JAK inhibitors leads to 
resistance to the drug (16). Interestingly, this resistance seems to be 
reversible and not due to the generation of new mutations in the JAK-STAT 
pathway (16). Our data suggest that the induction of resistance to I-BET151 
occurs at a much slower rate compared with the acquired JAKi resistance. We 
suggest that the use of the two inhibitors in combination, perhaps as an 
alternating dosage strategy, may prevent the establishment of JAK2i 
persistent cells.  
Recently, JAK2 inhibitors have been approved for the treatment of 
myelofibrosis as they show an improvement of the clinical symptoms of the 
pathology. However, the JAK2 inhibitors do not induce a strong and 
consistent reduction in the burden of JAK2V617F positive progenitor cells (14, 
32). The observed clinical effect of the JAK2 inhibitors may be mediated by 
non-specific targeting of JAK1 and JAK2 in both JAK2V617F negative and 
positive cells. The clinically approved JAK2 inhibitors have also been found to 
cause a range of adverse side effects. Our findings suggest that I-BET151 
represents a promising alternative treatment for JAK2V617F driven diseases, 
where combinatorial use of the both JAK and BET inhibitors may enhance our 
ability to target the neoplastic cells, while simultaneously reducing the risk of 
adverse side effects. 
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Figure Legends 
 
Figure 1 
I-BET151 inhibits growth and induces apoptosis in erythroleukemia cells. (A) 
Human erythroleukemia (HEL) and myelogenous leukemia (K562) cells were 
treated with a range of I-BET151 concentrations and the population doubling 
was monitored over 3 days. (B) Clonogenic assay performed in the presence 
of DMSO or 1µM I-BET151. (C) Immunoblotting demonstrating an increase in 
the cleaved PARP and active CASPASE 3 after 24h and 48h of I-BET151 
treatment. (D) Apoptosis was assessed by FACS analysis after 24h and 48h 
incubation with DMSO or 1µM I-BET151 by monitoring ANNEXIN V. 
 
Figure 2 
I-BET151 potently inhibits the expression of an important hematopoietic 
regulator, LMO2. Messenger RNA was isolated from HEL cells treated for 4h 
with 1µM I-BET151 or DMSO. Four biological replicates were analysed by 
microarray to generate a global gene expression profile. (A) Volcano plot for I-
BET151 against DMSO treated samples, showing the adjusted significance P 
value (-log10) versus fold change (log2). (B) The 46 most down-regulated 
genes are illustrated; shading highlights the position of LMO2 gene. (C) LMO2 
gene expression after treatment with 1µM I-BET151 was validated with qRT-
PCR. Data is normalized to B2M expression; the expression level of LMO2 in 
DMSO was assigned a value of 1 and the error bars reflect standard 
deviation. (D) Immunoblotting demonstrating reduced levels of LMO2 protein 
after treatment with 1µM I-BET151. 
 
Figure 3 
ChIP analysis at the LMO2 locus. (A) Schematic representation of LMO2 
locus. Black boxes indicate coding, and white boxes non-coding exons. 
Arrows mark transcription start sites. (B) Four regions within the LMO2 locus 
were investigated (amplicons 1–4; see schematic representation of LMO2 
locus) by chromatin immunoprecipitation analyses with antibodies against 
H3K4me3, panH4ac, BRD4, Pol II S2, and an integral member of the PAF 
complex, LEO1. Bar graphs are represented as the mean enrichment relative 
to input and error bars reflect standard deviation. 
 
Figure 4 
LMO2 is required for the continuous proliferation of erythroleukemia cells. (A) 
Knockdown of LMO2 in HEL cells results in a competitive growth 
disadvantage. HEL cells were transduced with constructs containing shRNA 
against LMO2 or empty vector as a control. GFP was included as an indicator 
of transduced cells and its presence was monitored for 13 days following 
infection. Percentages of GFP positive cells are indicated. Shown are the 
results from a representative experiment performed in duplicate. (B) shRNA 
knockdown validation by immunoblotting showing LMO2 protein disappearing 
at day 5 post-infection with shLMO2 retrovirus. (C) Knockdown of LMO2 
induces apoptosis in HEL cells. Immunoblotting showing the induction of 
PARP cleavage and (D) the activation of CASPASE 3 in cells transduced with 
shLMO2-1 and shLMO2-2. 
 
 
Figure 5 
JAK2i and I-BET151 induce similar transcriptional changes and cooperate in 
HEL cells. (A) Correlation of gene expression profiles induced by JAK2i and I-
BET151 in HEL cells. Log2 fold change values were scaled to have equal 
mean and variance and a threshold was selected which corresponded to an 
absolute fold change of 2.0 in the I-BET151 experiment. Genes significantly 
up-regulated by both inhibitors are represented as red hollow dots, while 
genes significantly down-regulated by both inhibitors are represented as blue 
hollow dots. Genes significantly regulated by only one of the two inhibitors are 
represented as green hollow dots. (B) Overlapping of gene sets significantly 
down-regulated by JAK2i and I-BET151. (C) Overlapping of gene sets 
significantly up-regulated by JAK2i and I-BET151. (D) HEL cell 72h 
proliferation assay using JAK2i and I-BET151 at the indicated concentrations 
individually or in combination. (E) LMO2 mRNA levels were analysed by RT-
qPCR in HEL cells after treatment with DMSO, 125nM I-BET151, 500nM 
JAK2i or a combination of the two inhibitors. 
 
Figure 6 
I-BET151 shows efficacy in samples isolated from patients with Polycythemia 
Vera (PV).  (A) Hematopoietic progenitor cells were isolated from whole blood 
obtained from a PV patient and treated with DMSO, 200nM I-BET151 or 1µM 
I-BET151. Expression of LMO2 was examined 4 hours after treatment. Data 
are normalized individually to Actin or GAPDH. The expression level of LMO2 
in DMSO was assigned a value of 1 and error bars reflect standard deviation 
of three biological replicates. (B) Peripheral blood mononuclear cells were 
isolated from a single PV patient and cultured in methylcellulose media 
supplemented with 1 unit/ml Epo and with either DMSO or I-BET151 at the 
concentrations indicated. BFU-E colonies were genotyped after 14 days in 
culture. The numbers at the top of the graph show the number of colonies 
genotyped for JAK2V617F mutation over total colonies derived from plating 
1.6X106 cells. The Y-axis shows the relative percentages of homozygous 
JAK2V617F colonies (Hom; red), heterozygous JAK2V617F colonies (Het; 
pink) and wild type JAK2 colonies (WT; white). (C) The BFU-E assay was 
repeated in a further 3 PV patients in the presence of DMSO or 200nM I-
BET151 and the results are presented as described for panel (C). 
 
Figure 7 
I-BET is effective against JAK2i resistant HEL cells. (A) Schematic 
representation of the strategy used to establish JAK2i and I-BET151 
persistent cells. (B) Concentration increase over time during the 
establishment of JAK2i persistent cells. (C) Concentration increase over time 
during the establishment of I-BET151 persistent cells.  (D) HEL cells 72h 
proliferation assay. The indicated cells were treated with 250nM JAK2i and 
counted after 72h proliferation. The indicated values are expressed as % of 
the DMSO treated control cells. (E) HEL cells 72h proliferation assay. The 
indicated cells were treated with 125nM I-BET151 and counted after 72h 
proliferation. The indicated values are expressed as % of the DMSO treated 
control cells. 
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Fall 
Change  
Gene  
Symbol 
Fall 
Change  
1 APLNR 0.17 51 ZMYND8 0.40 
2 ARHGAP22 0.21 52 ZMYND8 0.40 
3 LMO2 0.21 53 SLC19A1 0.41 
4 NFIB 0.25 54 NRXN2 0.41 
5 NA 0.25 55 NA 0.41 
6 TNS3 0.27 56 UBASH3B 0.41 
7 ITLN2 0.27 57 PRDM10 0.41 
8 IL1B 0.28 58 NA 0.41 
9 ARHGAP39 0.28 59 F2RL2 0.41 
10 ANKRD55 0.28 60 IGFBP5 0.42 
11 NEK6 0.29 61 NA 0.42 
12 RFESD 0.29 62 GAPT 0.42 
13 NA 0.29 63 MLKL 0.42 
14 TUBAL3 0.30 64 MGAT3 0.42 
15 KCNH2 0.30 65 PSKH2 0.42 
16 GYPE 0.31 66 GRAP2 0.43 
17 GYPE 0.31 67 GJA1 0.43 
18 MOBKL2B 0.31 68 RGS18 0.43 
19 IGFBP5 0.32 69 GAPT 0.44 
20 TGM5 0.32 70 PLCH1 0.44 
21 WNT5B 0.32 71 PRR5 0.44 
22 *MARCH4 0.32 72 SH3PXD2A 0.44 
23 PLD6 0.32 73 ERMAP 0.44 
24 RFESD 0.33 74 ADORA2B 0.45 
25 C1orf186 0.33 75 RAB3IL1 0.45 
26 PRICKLE1 0.34 76 LAT 0.45 
27 DARC 0.34 77 GDF3 0.45 
28 F2R 0.35 78 TOMM40L 0.45 
29 TRIM15 0.35 79 NA 0.45 
30 RFESD 0.36 80 PIM1 0.45 
31 HEMGN 0.37 81 ARHGAP25 0.45 
32 GFRA2 0.37 82 FEZ1 0.45 
33 LTB 0.37 83 ADCYAP1 0.45 
34 VAV3 0.37 84 ANGPT1 0.46 
35 HEMGN 0.37 85 RSAD2 0.46 
36 DHRS3 0.38 86 MTSS1 0.46 
37 AMHR2 0.38 87 CHCHD4 0.46 
38 F2RL3 0.38 88 TUBB1 0.46 
39 LIN28B 0.38 89 TGM5 0.46 
40 NA 0.38 90 ITGA4 0.46 
41 TRIM15 0.38 91 ZNF692 0.46 
42 RASGRP3 0.39 92 *MARCH2 0.46 
43 LRRC32 0.39 93 RBM12 0.46 
44 NA 0.39 94 TMEM223 0.47 
45 HMBS 0.39 95 RAB33A 0.47 
46 SLC45A3 0.39 96 KAZN 0.47 
47 TRIB2 0.39 97 MMACHC 0.47 
48 TRIM10 0.39 98 PTPN22 0.47 
49 ICAM2 0.39 99 TRIB1 0.47 
50 MYB 0.40 100 NFE2 0.47 
Gene  
Symbol 
Fall 
Change 
Gene  
Symbol 
Fall 
Change 
1 TUBB3 6.00 51 ERRFI1 2.70 
2 HIST1H2BD 5.43 52 CSRNP2 2.70 
3 SERTAD1 4.80 53 C12orf34 2.70 
4 IRF7 4.70 54 PELI1 2.66 
5 IRF7 4.56 55 SERPINE2 2.65 
6 HES6 4.53 56 PRDM2 2.63 
7 TUFT1 4.40 57 MT1A 2.63 
8 MARCKSL1 4.10 58 CHCHD7 2.62 
9 BTG1 4.08 59 CHCHD7 2.60 
10 HIST2H2BE 4.06 60 HIST2H4A 2.57 
11 SERPINI1 3.94 61 KIF1B 2.56 
12 HIST1H2AC 3.93 62 KLHL7 2.55 
13 HIST2H2AA3 3.80 63 CDO1 2.55 
14 CSRP2 3.72 64 PLEKHO2 2.53 
15 NEU1 3.68 65 DGAT1 2.52 
16 NDRG1 3.46 66 IER5 2.52 
17 ZCCHC12 3.29 67 MT2A 2.52 
18 MT1X 3.25 68 NA 2.50 
19 RGS2 3.23 69 ATP1B1 2.50 
20 HIST2H2AA4 3.21 70 TUBB2A 2.50 
21 SERPINI1 3.21 71 HIST1H2BG 2.49 
22 CSRNP2 3.18 72 HIST1H2BD 2.48 
23 MKNK2 3.14 73 RELL1 2.47 
24 LFNG 3.13 74 H2AFJ 2.47 
25 MKNK2 3.13 75 FBXO33 2.46 
26 RHPN2 3.12 76 RFC3 2.45 
27 CDO1 3.12 77 EGR1 2.45 
28 NXF1 3.09 78 ABHD3 2.44 
29 CDKN1A 3.08 79 FGFRL1 2.44 
30 VAMP1 3.07 80 RPPH1 2.43 
31 NXF1 3.07 81 TAX1BP3 2.43 
32 MT1E 3.05 82 ELOVL4 2.43 
33 TESK2 3.02 83 NFKBIZ 2.42 
34 NA 3.01 84 NA 2.42 
35 TM7SF2 2.98 85 WDR47 2.42 
36 MT1G 2.98 86 HIST2H2AC 2.41 
37 TOB1 2.88 87 OPN3 2.40 
38 HIST3H2A 2.86 88 NA 2.40 
39 HIST2H2AA3 2.84 89 HNRNPA2B1 2.39 
40 NA 2.81 90 HIST1H2BK 2.39 
41 TUBB2C 2.79 91 JUP 2.39 
42 TEX14 2.76 92 MIDN 2.39 
43 HIST1H2BK 2.76 93 TXNIP 2.37 
44 GLS 2.76 94 HIST1H4H 2.37 
45 SLC9A1 2.75 95 SLC30A3 2.36 
46 SAT1 2.74 96 EPB41L5 2.36 
47 FAM107B 2.73 97 DACT3 2.36 
48 HIST1H2BJ 2.73 98 EPB41L5 2.36 
49 NA 2.73 99 MXD4 2.36 
50 MT1H 2.71 100 CCDC92 2.36 
A B
Supplementary Figure S1
The top 100 genes (A) down-regulated, and (B) up-regulated in HEL cells after treatment with 1μM I-BET151 
for 4 hours.
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Supplementary Figure S2
The expression changes of seven genes in response to 4 hours treatment with 1μM I-BET151 were validated 
by qRT-PCR. Three down-regulated genes (A) NEK6, (B) MYB, (C) LMO2, one gene unresponsive to I-BET151 
treatment (D) CISH, and three up-regulated genes (E) BTG1, (F) IRF7, (G) VAMP1, were analysed.
Supplementary Figure S2
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Supplementary Figure S3
Knockdown of LMO2 in K562 cells (A) K562 cells were transduced with constructs containing shRNA 
against LMO2 or the empty vector as a control. GFP presence was monitored over 13 days after 
infection and percentages of GFP positive cells are indicated. Shown are the results from a represen-
tative experiment performed in duplicate, (B) shRNA knockdown validation by immunoblotting show-
ing LMO2 protein disappearing at day 5 post-infection with shLMO2-1 and shLMO2-2, (C) Immunob-
lotting demonstrating levels of cleaved PARP in cells transduced with shLMO2 and control virus, (D) 
Immunoblotting showing levels of active caspase 3.
Supplementary Figure S3
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Supplementary Figure S4
The eect of I-BET151 and JAK2i (TG101209) inhibitors on HEL cell and K562 cell growth. (A) JAK2i 
(TG101209) in HEL cells (B) I-BET151 in HEL cells, (C) JAK2i (TG101209) in K562 cells (D) I-BET151 in K562 cells. 
Data are represented as mean of three independent experiments. Error bars represent standard deviation.
Supplementary Figure S4
Supplementary Figure S5
Cooperation of I-BET151 and JAK2i on HEL cells. HEL cells 72h proliferation assay. 105 cells were plated and treated with 
the indicated concentration of the two inhibitors or DMSO as negative control. 
Supplementary Figure S6
JAK2i and I-BET151 eects on LMO2 repression.  LMO2 expression levels were analyzed by RT-qPCR in HEL cells treated for 4h with the 
indicated concentration of I-BET151 and JAK2i or DMSO. Expression levels relative to GAPDH are shown. 
Supplementary Figure S7
HEL cells 72h proliferation assay. HEL cells were treated with the indicated concentrations of (A) JAK2i or (B) I-BET151 and 
counted after 72h proliferation. The indicated values are expressed as % of the DMSO treated control cells.
Supplementary Figure S8
(A) HEL cells 72h proliferation assay. The indicated cells were treated with 1000nM JAK2i and counted after 72h prolif-
eration. The indicated values are expressed as % of the DMSO treated control cells. (B) HEL cells 72h proliferation assay. 
The indicated cells were treated with 1000nM I-BET151 and counted after 72h proliferation. The indicated values are 
expressed as % of the DMSO treated control cells.
